These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Author: Barginear M, Clotfelter A, Poznak CV.
    Journal: Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386.
    Abstract:
    The aromatase inhibitors have been widely incorporated into the adjuvant breast cancer care of postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer. Aromatase inhibitor use is associated with an increased risk of lowering bone mineral density and accelerating the risk of fragility fractures. Optimizing bone health includes appropriate nutrition and exercise, as well as screening for and treatment of low bone mass. Assessment of an individual's risk of fracture typically includes measuring the bone mineral density and other clinical risk factors, and there are evolving data as to the potential added information obtained by measuring biochemical markers of bone metabolism.
    [Abstract] [Full Text] [Related] [New Search]